Differences in Helicobacter pylori and CagA antibody changes after eradication between subjects developing and not developing gastric cancer

Masaaki Kodama,1,2,* Tadayoshi Okimoto,1 Kazuhiro Mizukami,1 Kensuke Fukuda,1 Ryo Ogawa,1 Kazuhsa Okamoto,1 Osamu Matsunari,1 Yoshinari Kawahara,1 Yuka Hirashita1 and Kazunari Murakami1

1Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Iidaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan
2Faculty of Welfare and Health Science, Oita University, 700 Dannoharu, Oita 870-1192, Japan

(Received 10 April, 2019; Accepted 26 April, 2019; Published online 11 June, 2019)

We evaluated serological Helicobacter pylori and cytotoxin-associated gene A (CagA) antibodies and endoscopic atrophy after eradication to identify factors predicting post-eradication gastric cancer development. Thirty-five patients with successful eradication were divided into the post-eradication gastric cancer (13 cases) and non-gastric cancer (22 cases) groups. Serum Helicobacter pylori and CagA antibody titers and endoscopic atrophy before and six years after eradication were examined. Median Helicobacter pylori antibody titers had decreased significantly from baseline at 0.5–2 years after eradication in both groups (gastric cancer group, from 39.0 to 11.0 U/ml, p = 0.011; non-gastric cancer group, from 29.6 to 4.97 U/ml, p < 0.001), but were significantly higher in the gastric cancer than in the non-gastric cancer group (p = 0.029). Median serum CagA antibody titers had also decreased significantly at 0.5–2 years after eradication (gastric cancer group, from 6.35 to 3.23 U/ml, p = 0.028; non-gastric cancer group, from 9.88 to 1.21 U/ml, p = 0.0045). Serum CagA in each group showed no significance. Endoscopic atrophy improved significantly after eradication in the non-gastric cancer, but not the gastric cancer, group (p = 0.0007). In conclusion, changes in Helicobacter pylori and CagA antibody titers and endoscopic atrophy after eradication might be useful as predictive factors for post-eradication gastric cancer.

Key Words: Helicobacter pylori, eradication, gastric cancer, Helicobacter pylori antibody, CagA antibody

Helicobacter pylori (HP) has been proven to be a major risk factor in gastric cancer (GC).1,2 Many studies have demonstrated that HP eradication (HPE) is associated with the reduction of GC.1–7 The World Health Organization’s International Agency for Research on Cancer Working Group recognized that HP causes almost 90% of non-cardiac cancers, and that HPE decreases GC approximately 30–40% of cases.8 Thus, HPE cannot abolish the development of GC completely. Therefore, predictive and risk factors for GC discovered after HPE should be identified.

Serological evaluation with anti-HP immunoglobulin G (IgG) antibody testing is an inexpensive and noninvasive method that is used commonly throughout the world for the diagnosis of HP-related conditions.9 Because HP IgG antibody titers may remain elevated for 6–12 months after HPE, serological testing to establish HPE should be performed at least 6–12 months post-treatment.9 Serological testing has also been used in ABC risk classification to evaluate GC risk.11

Cytotoxin-associated gene A (CagA) is among the best-studied HP virulence factors.12 CagA injected into gastric epithelial cells by the bacterium binds to Src homology-2 domain-containing phosphatase and induces morphological changes and damage in these cells, which have been reported to lead to gastric carcinogenesis.13,14 Serological testing with anti-CagA antibody measurement thus provides important information about GC status.15 In one study, risk for GC development determined by HP and -CagA antibody positivity were 2.28 and 2.87 fold increases.15 Our previous study also showed that CagA seropositivity was associated closely with the risk of GC development.16

The identification of post-HPE GC risk factors would be very useful for GC screening. Several characteristics of GC arising after HPE and differences from that developing before HPE have been reported.17–19 However, almost all risk factors for post-HPE GC, including endoscopic and histological atrophy, are identified before HPE.20–22 Few reports have described GC risks detected after HPE.23 The characterization of changes in the gastric mucosa and serological status after HPE is very important for the early detection of GC development. Because serological testing is easily performed, inexpensive, and informative about GC risk, in this study we evaluated changes in serological HP and CagA antibody titers and endoscopic atrophy after HPE in the effort to identify risk factors for post-HPE GC development.

Materials and Methods

Subjects. We performed a retrospective, case-control study. In this study, data from patients who underwent gastrointestinal endoscopy and were diagnosed as HP positive at Oita University Hospital between January 1988 and December 2009 were evaluated. The diagnosis of HP infection was based on rapid urease test (RUT), culture, and/or histological positivity. HPE treatment was administered to all patients. Serum HP and CagA antibody status and endoscopic atrophy were evaluated in these patients with successful eradication up to seven years. The patients were retrospectively divided into GC and non-GC groups according to the development of GC after HPE. Background diseases of all patients were compared in both groups. The study protocol was approved by an institutional review board of Oita University, Faculty of Medicine (987). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the

*To whom correspondence should be addressed.
E-mail: kodm@oita-u.ac.jp
Serum HP and CagA antibody titer evaluation. The serum HP and CagA antibody titers of all patients were measured. Serum HP IgG antibody titers were measured by enzyme-linked immunosorbent assay (ELISA) using the E-Plate II Eiken (Eiken Chemical Co., Ltd., Tokyo, Japan). According to the manufacturer’s instructions, values exceeding 10 U/ml were considered to be positive. Serum CagA IgG antibody titers were measured using the CagA ELISA kit (Genesis Diagnostics Ltd., Cambridgeshire, UK) and the manufacturer’s positivity threshold of >6.25 U/ml.

Endoscopic atrophy. Endoscopic examinations were performed using Olympus endoscopes (models Q-260, Q-290, HQ-290, and others; Tokyo, Japan). Endoscopic atrophy was diagnosed using the endoscopic atrophic-border scale of Kimura and Takemoto. This scale correlates with histological atrophy grades determined before and after HPE: 1) closed (C) type, in which the atrophic border remains on the lesser curvature of the stomach; and 2) open (O) type, in which the atrophic border extends along the anterior and posterior walls of the stomach and is not associated with the lesser curvature. The grade of atrophy was further classified into C0, C1, C2, C3 and O1, O2, O3. Each atrophy status were scored, as C0–C3 (0 to 3) and O1–O3 (4 to 6). Score 0 indicated that atrophy was absence and score 6 indicated that atrophy was most severe.

Statistical analysis. Statistical analyses were performed using SPSS software (SPSS Statistics 22; IBM, Armonk, NY). Titer data included in the study.

**Results**

Patient characteristics. The sample comprised 35 patients. HPE treatment was successful in all patients, with negative RUT, culture, and histological results. In 13 cases (9 males, 4 females; mean age at HPE, 62.7 ± 10.4 years), GC was discovered after HPE. In 22 cases (16 males, 6 females; mean age at HPE, 55.4 ± 9.6 years), no GC developed after HPE (Table 1). The age at the time of HPE was significantly greater in the GC group than in the non-GC group (p = 0.021). The mean interval between HPE and the discovery of GC was 63.3 ± 56.2 months. Background upper gastrointestinal diseases (GC group/non-GC group) were chronic gastritis (5/11), gastric ulcer (GU; 4/5), duodenal ulcer (DU; 0/3), gastroduodenal ulcer (GU; 4/5), and mucosa-associated lymphoid tissue lymphoma (1/0; Table 1). The GU/DU ratio did not differ between the GC (4/0) and non-GC (5/3) groups.

Serum CagA and HP antibody seropositivity and titers. Before HPE, the rates of serum CagA antibody positivity were 61.5% (8/13) in the GC group and 54.5% (12/22) in the non-GC group, with no significant difference between groups (Table 2). The OR for CagA antibody positivity in the GC group was 1.33 (95% CI, 0.340–5.173; p = 0.69).

The median serum HP antibody titers (GC group/non-GC group) were 39.0 ± 29.6 U/ml before HPE (p = 0.22), 11.0 ± 4.97 U/ml at 0.5–2 years after HPE (p = 0.029), 7.37 ± 3.0 U/ml at 2–5 years after HPE (p = 0.26), and 2.10 ± 2.41 U/ml at 5–7 years after HPE (p = 0.16; Fig. 1). Relative to pre-HPE values, HP antibody titers had decreased significantly from 0.5–2 years after HPE in both groups (GC group, p = 0.011; non-GC group, p < 0.001).

### Table 1. Characteristics of patients who did and did not develop gastric cancer following *Helicobacter pylori* eradication

| Characteristic                          | Gastric cancer group | Non-gastric cancer group | p       |
|-----------------------------------------|----------------------|--------------------------|---------|
| Number of patients                      | 13                   | 22                       |         |
| Sex (male/female)                       | 9/4                  | 16/6                     | 0.825<sup>a</sup> |
| Age at *Helicobacter pylori* eradication (years) | 62.7 ± 10.4          | 55.4 ± 9.6               | 0.021<sup>b</sup> |
| Age at gastric cancer detection (years)  | 67.8 ± 10.1          | —                        | —       |
| Observation period after eradication (months) | 63.3 ± 56.2          | —                        | —       |
| Background disease at eradication       |                      |                          |         |
| Chronic gastritis                       | 5                    | 11                       |         |
| GU                                      | 4                    | 5                        |         |
| DU                                      | 0                    | 3                        |         |
| Gastroduodenal ulcer                    | 0                    | 1                        |         |
| Gastric cancer                          | 3                    | 1                        |         |
| Gastric adenoma                         | 0                    | 1                        |         |
| MALT lymphoma                           | 1                    | 0                        |         |
| GU/DU                                   | 4/0                  | 5/3                      | 0.157<sup>c</sup> |

Data are presented as numbers or means ± SDs. *Chi-squared test, †Student’s t test, ‡Fisher’s exact test. GU, gastric ulcer; DU, duodenal ulcer; MALT, mucosa-associated lymphoid tissue.

### Table 2. CagA seropositivity before *Helicobacter pylori* eradication

| Group                        | Serum CagA antibody | OR     | 95% CI         | p       |
|------------------------------|---------------------|--------|----------------|---------|
| Positive                     | 8 (61.5%)           | 5      | 1.33           | 0.340–5.173 | 0.686<sup>a</sup> |
| Non-gastric cancer           | 12 (54.5%)          | 10     |                |         |

OR, odds ratio; 95% CI, 95% confidence interval; <sup>a</sup>Chi-squared test.
The median serum CagA antibody titers (GC group/non-GC group) were 6.35/9.88U/ml before HPE ($p=0.43$), 3.23/1.21U/ml at 0.5–2 years after HPE ($p=0.49$), 0.72/0.66 U/ml at 2–5 years after HPE ($p=0.46$; Fig. 2). Both groups showed no significant difference during the observation period. Relative to pre-HPE values, CagA antibody titers after eradication had decreased significantly from 0.5–2 years to 5–7 years after HPE in both groups (GC group, $p=0.0278$; non-GC group, $p=0.0045$).

**Discussion**

HP infection has close association with not only gastroduodenal diseases, but also many systemic inflammation and diseases. Although contradictory results were reported, several studies described that HPE improved serum lipid metabolism\(^{(27)}\) and the nutrition status in hemodialysis patients.\(^{(28)}\)

HPE is known to reduce the potential for gastric carcinogenesis,\(^{(3–8)}\) but it cannot completely suppress GC development. The incidence of post-HPE GC has increased gradually with the number of subjects in whom HPE has been achieved. Although factors associated with post-HPE GC, such as advanced age at the time of HPE, male sex, severe atrophy, and intestinal metaplasia,\(^{(4,20–22)}\) have been reported, these factors are observed before HPE. Few data are available on predictive factors that are detected after HPE; only map-like erythema appearing on the gastric mucosa after HPE has been reported as a risk factor for GC development.\(^{(23)}\) In this study, changes in HP and CagA antibody titers and endoscopic atrophy were evaluated to identify post-HPE risk factors for GC.

The use of serum HP antibody testing is widespread, given its utility for mass screening for HP infection.\(^{(9)}\) However, it is unsuitable for the rapid evaluation of HPE, as titers decrease only 6–12 months after HPE.\(^{(10)}\) In this study, HP antibody titers had declined significantly at 0.5–2 years after HPE relative to baseline ($p=0.0007$); the GC group showed no such change ($p=0.12$).
group than in the non-GC group during this period, culture, histological and RUT findings were negative, suggesting that some cases in the GC group produced false-negative results for all tests. The rate of GC development is typically higher in patients with HP infection than in those in whom HPE has been achieved. Alternatively, HP antibody titers may have decreased more slowly in several cases in the GC group relative to the non-GC group. Another possible explanation is related to the immunohistochemical detection of HP in the lamina propria, whereas it is usually present on the surface of the gastric mucosa. To et al. described the detection of HP in the gastric lymph nodes along the lesser curvature of the stomach in 21–37 of 46 patients with HP infection by culture, polymerase chain reaction, and immunohistochemistry. HP was detected in many macrophages and a few interdigitating dendritic cells. The authors suggested that the bacterium invaded through gastric mucosal damage and translocated to the gastric lymph nodes, with resulting effects on the immune system associated with chronic gastritis, which may in turn contribute to post-HPE gastric carcinogenesis. The slow reduction of HP antibody titers after HPE treatment may reflect a delay in the eradication of bacteria that have invaded the lymph nodes, and thus an increased risk of GC development.

CagA was the representative HP pathogenic factor examined in this study. The risk of GC development has been shown to be higher (by 1.64 times) in patients infected with CagA-positive HP strains than in those infected with CagA-negative strains. The CagA protein is structurally diverse, divided into Western and East-Asian types. In Japan, most HP strains have the East-Asian type of CagA, which has stronger cytotoxicity and a closer association with gastric carcinogenesis than does the Western type. The East-Asian CagA strain has been associated significantly with severe atrophic gastritis, intestinal metaplasia, and GC development relative to the Western type. CagA antibody seropositivity is associated closely with GC in East-Asian countries, such as Japan, Korea, and China, despite differences in populations, the antigens used for CagA antibody. Therefore, the CagA antibody is a useful biomarker for GC especially in East Asia. However, the rate of seropositivity for this antibody in our sample was only 61.5%. In Japan, most HP strains are CagA positive; Shiota et al. reported that 96.3% of strains were positive for the cagA gene. However, extremely high CagA seropositivity is not often seen, even in East Asian countries. In our previous study, the CagA seropositivity ratio was 75.0%, and CagA antibody titers were associated significantly with the serum pepsinogen level, atrophic gastritis, and GC. Shimoyama et al. reported CagA antibody positivity rates of 60% (49/81) for GC cases and 44% for non-GC cases (36/81) in a Japanese sample. These rates are comparable to those found in the present study.

Although the CagA antibody seropositivity rate tended to be higher in the GC group than in the non-GC group in this study, this difference was not significant. Kikuchi et al. reported that both CagA antibody positivity and negativity were related to the risks of intestinal-type, diffuse-type, early, advanced, proximal, and distal GC in subjects with HP infection, despite the serum CagA positivity rate of about 60%. Consequently, our results also reflect the close relationship between CagA seropositivity and GC development.

In addition, 0.5–2 years after HPE, CagA antibody titers were higher in the GC group than in the non-GC group. Thus, these titers seemed to decrease more slowly in the GC group, but both groups showed no significance. As for the HP antibody titers, some cases may have yielded false-negative results. CagA is injected into the cytoplasm of gastric epithelial cells, and is detected even in nuclear fractions. Lim et al. described CagA translocation into human B lymphocytes. Thus, deep CagA translocation might be associated with the slow decrease in CagA antibody titers and with the development of GC.

Several studies have demonstrated the association between endoscopic and histological atrophy. In our previous study, histological atrophy and intestinal metaplasia were correlated even after HPE. In addition, in a previous study we found significantly more severe endoscopic atrophy in the post-HPE GC group than in the non-GC group. The present result does not contradict these previous findings. No report has described a correlation between endoscopic atrophy and GC after HPE. To our knowledge, this study is the first to demonstrate the lack of a significant change in endoscopic gastric atrophy after HPE in the GC group, in contrast to the non-GC group.

As atrophy becomes severe, intestinal metaplasia also becomes severe. Similarly, intestinal metaplasia has been reported to increase the risk of GC after HPE. As an improvement in intestinal metaplasia is difficult to achieve after HPE, the same may have been true for endoscopic atrophy in the GC group compared with the non-GC group. In addition, because the high HP antibody titers at 0.5–2 years after HPE suggest the presence of false-negative cases, HP and CagA localized outside the gastric mucosa might have influenced chronic inflammation in these patients.

One limitation of this study is the small sample. Further examination of larger numbers of subjects is needed to clarify the association between HP and CagA seropositivity and GC development after HPE. Second, there were few measurement opportunities during the observation period. If observation time was more frequent, the comparison of both groups may be possible.

In conclusion, significantly high HP antibody titers were observed in the short term after HPE in the GC group. Additionally, endoscopic atrophy was significantly more severe before HPE and showed no significant improvement after HPE in the GC group compared with the non-GC group. Changes in HP and CagA antibody titers and endoscopic atrophy after HPE might be useful as predictive factors for post-HPE GC development. Additional studies are needed to further clarify these associations.

Author Contributions

MK: study concept and design, acquisition of data, analysis and interpretation of data and statistical analysis; TO, KM, and KF: acquisition of data, analysis and interpretation of data; RO, KO, OM, YK, and YH: acquisition of data; KM: drafting of the manuscript, obtained funding, administrative, technical, or material support and study supervision.

Acknowledgments

We thank the members of Department of Gastroenterology of Oita University; Ms. Yoko Kudo for data collection, analysis and interpretation of data.

Abbreviations

CagA cytoxin-associated gene A
DU duodenal ulcer
ELISA enzyme-linked immunosorbent assay
GC gastric cancer
GU gastric ulcer
HP Helicobacter pylori
HPE Helicobacter pylori eradication
IgG immunoglobulin G
MAL T mucosa-associated lymphoid tissue
RUT rapid urease test

Conflict of Interest

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

74 doi: 10.3164/jcbn.19-30 ©2019 JCBN
References

1 Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789.
2 Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–1186.
3 Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392–397.
4 Take S, Mirano M, Ishiki K, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol 2015; 50: 638–644.
5 Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g1174.
6 Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150: 1113–1124.
7 Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2019; 22: 435–445.
8 Herrero R, Park JY, Forman D. The fight against gastric cancer - the IARC Working Group report. Best Pract Res Clin Gastroenterol 2014; 28: 1107–1114.
9 Formichella L, Romberg L, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993; 90: 5791–5795.
10 Cutler AF, Prasad VM. Long-term follow-up of Helicobacter pylori serology after successful eradication. Am J Gastroenterol 1996; 91: 85–88.
11 Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels – “ABC method”. Proc Jpn Acad Ser B, Physiol Sci 2011; 87: 405–414.
12 Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993; 90: 5791–5795.
13 Higashi H, Tsutsui R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002; 295: 683–686.
14 Azuma T, Yamazaki S, Yamakawa A, et al. Association between diversity in the Srg homology 2 domain-containing tyrosine phosphatase binding site of Helicobacter pylori CagA protein and gastric atrophy and cancer. J Infect Dis 2004; 189: 820–827.
15 Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636–1644.
16 Shiota S, Matsunari O, Watada M, Yamaoka Y. Serum Helicobacter pylori CagA antibody as a biomarker for gastric cancer in east-Asian countries. Future Microbiol 2010; 5: 1885–1893.
17 Shiokami A, Nishi R, Uedo N, et al. Helicobacter pylori eradication prevents extension of intestinalization even in the high-risk group for gastric cancer. Digestion 2010; 81: 223–230.
18 Yamamoto K, Kato M, Takahashi M, et al. Clinicopathological analysis of early-stage gastric cancers detected after successful eradication of Helicobacter pylori. Helicobacter 2011; 16: 210–216.
19 Kodama M, Okimoto T, Mizukami K, et al. Endoscopic and immunohistochemical characteristics of gastric cancer with versus without Helicobacter pylori eradication. Digestion 2018; 97: 288–297.
20 Kamada T, Hata J, Sugii K, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther 2005; 21: 1121–1126.
21 Kodama M, Murakami K, Okimoto T, et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013; 48: 1249–1256.
22 Mori G, Nakajima T, Asada K, et al. Incidence of and risk factors for metachronous gastric cancer after endoscopic resection and successful Helicobacter pylori eradication: results of a large-scale, multicenter cohort study in Japan. Gastric Cancer 2016; 19: 911–918.
23 Moributa K, Iuchi JK, Nakachi K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by Helicobacter pylori eradication. Dig Endosc 2016; 28: 434–442.
24 Kimura M, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87–97.
25 Quach DT, Le HM, Hiyama T, Nguyen OT, Nguyen TS, Uemura N. Relationship between endoscopic and histologic gastric atrophy and intestinal metaplasia. Helicobacter 2013; 18: 151–157.
26 Kodama M, Okimoto T, Ogawa R, Mizukami K, Murakami K. Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia. Endosc Int Open 2015; 3: E311–E317.
27 Adachi K, Mishiro T, Toda T, et al. Effects of Helicobacter pylori eradication on serum lipid levels. J Clin Biochem Nutr 2018; 62: 264–269.
28 Ichikawa H, Sugimoto M, Sakao Y, et al. Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: a pilot study. J Clin Biochem Nutr 2019; 64: 91–95.
29 Andersen LP, Holck S. Possible evidence of invasiveness of Helicobacter (Campylobacter) pylori. Eur J Clin Microbiol Infect Dis 1990; 9: 135–138.
30 Mai UE, Perez-Perez GI, Allen JB, Wahl SM, Blaser MJ, Smith PD. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med 1992; 175: 517–525.
31 Ito T, Kobayashi D, Uchida K, et al. Helicobacter pylori invades the gastric mucosa and translocates to the gastric lymph nodes. Lab Invest 2008; 88: 664–681.
32 Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114: 1169–1179.
33 Yamaoka Y, El-Zimaity HM, Gutierrez O, et al. Relationship between the cagA 3’ repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology 1999; 117: 342–349.
34 Abe T, Kodama M, Murakami K, Matsunari O, et al. Impact of Helicobacter pylori CagA diversity on gastric mucosal damage: an immunohistochemical study of East-Asian-type CagA. J Gastroenterol Hepatol 2011; 26: 688–693.
35 Shiota S, Murakami K, Okimoto T, Kodama M, Yamaoka Y. Serum Helicobacter pylori CagA antibody titer as a useful marker for advanced inflammation in the stomach in Japan. J Gastroenterol Hepatol 2014; 29: 67–73.
36 Shimoyama T, Fukuda S, Tanaka M, Mikami T, Munakata A, Crabtree JE. CagA seropositivity associated with development of gastric cancer in a Japanese population. J Clin Pathol 1998; 51: 225–228.
37 Kikuchi S, Crabtree JE, Forman D, Kuroasawa M. Association between infections with CagA-positive or -negative strains of Helicobacter pylori and risk for gastric cancer in young adults. Research Group on Prevention of Gastric Carcinoma Among Young Adults. J Am Med Assoc 1999; 282: 3455–3459.
38 Uchida T, Kanada R, Tsukamoto Y, et al. Immunohistochemical diagnosis of the cagA-gene genotype of Helicobacter pylori with anti-East Asian CagA-specific antibody. Cancer Sci 2007; 98: 521–528.
39 Lim JH, Kim SG, Choi J, Im JP, Kim JS, Jung HC. Risk factors for synchronous or metachronous tumor development after endoscopic resection of gastric neoplasms. Gastric Cancer 2015; 18: 817–823.
40 Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc 2016; 84: 618–624.